FDA Clarifies MIDD Paired Meeting Program Rules for Sponsors Navigating IND Strategy

The FDA's MIDD Paired Meeting Program carries direct implications for clinical pharmacology teams and regulatory affairs leads managing active development programs: sponsors can now engage the Agency on model-informed drug development questions at any stage, from preclinical through late-phase, provided an active PIND or IND is on file and a clearly defined development issue is in hand.

The program differs meaningfully from the legacy End of Phase 2A meeting framework. Under EOP2A, FDA staff historically conducted extensive modeling and simulation internally. Under MIDD, that practice is not routine, the Agency's focus shifts to conceptual alignment on proposed approaches rather than independent model execution. For QA and regulatory leads, that distinction affects how meeting packages should be scoped: sponsors carry more of the analytical preparation burden upfront.

Confidentiality protections mirror those governing standard Type C meetings under existing FDA regulations, meaning sponsor-specific information remains protected. The Agency has indicated it will publish aggregate program metrics and lessons learned from the pilot, but no program-specific disclosures will occur without sponsor consent. Sponsors evaluating whether to participate can treat the confidentiality posture as equivalent to a conventional regulatory submission.

Eligibility review sits with a Selection Committee drawn from senior staff across CDER, including the Office of Clinical Pharmacology, Office of Biostatistics, Office of New Drugs, and Office of Regulatory Policy, and CBER's Office of Biostatistics and Pharmacovigilance. Proposals are assessed on two criteria: meeting eligibility requirements and presenting a pertinent development issue where regulatory input on a model-informed strategy would materially advance the program.

Developers of new biological entities are explicitly within scope, including those working from preclinical data only. First-in-human study design questions informed by non-clinical in vivo and toxicology data qualify for submission. Meeting outcomes will not constitute broad model qualification for general contexts of use; rather, they may yield specific agreement on a model-based approach tied to the development question at hand, a distinction that matters for how teams document and reference meeting outcomes in subsequent submissions.

For reference frameworks on model risk assessment methodology, the Agency points to Madabushi et al. 2024 (PMID: 38445751) and Kuemmel et al. 2020 (PMID: 31652029) as published examples sponsors can use when structuring their proposals.

The program's expansion beyond EOP2A milestones and its openness to preclinical-stage biologics developers signals a measurable shift in how early FDA engagement on quantitative modeling can be structured into development timelines.

Source: FDA Center for Drug Evaluation and Research via FDA.gov, July 7, 2026.